Suppr超能文献

右美托咪定降低大鼠对氟烷的麻醉需求。

Dexmedetomidine decreases halothane anesthetic requirements in rats.

作者信息

Segal I S, Vickery R G, Maze M

出版信息

Acta Vet Scand Suppl. 1989;85:55-9.

PMID:2571278
Abstract

alpha 2-Adrenergic agonists, such as clonidine, reduce the dose requirements for halothane. Medetomidine is more selective as a full agonist for central alpha 2-adrenoceptors than clonidine and is available as both an active (d) and an inactive (l) isomer. We have used the d-isomer to probe the mediating mechanism for the MAC-sparing effect of this alpha 2-agonist in rats. The dose of halothane which rendered 50% of animals insensitive to a painful stimulus (halothane MAC) was determined in rats (150-200 g) before and after d- or l-medetomidine, 10, 30 and 100 micrograms/kg or saline i.p. To determine whether alpha 2-adrenoreceptors mediated the MAC-sparing effect of dexmedetomidine (d-medetomidine), cohorts of rats (n = 6 for each dose) were pretreated with idazoxan, 10 mg/kg i.p., the highly selective alpha 2-antagonist. To determine whether dexmedetomidine's MAC-reducing action was mediated in part through either opiate or adenosine receptors, groups of rats were pretreated with either naltrexone, 5 mg/kg i.p., an opiate antagonist; or 8-phenyltheophylline (8-PT), 2.5 mg/kg i.p., an A1 adenosine antagonist. To determine whether postsynaptic mechanisms mediate the anesthetic-sparing effect of dexmedetomidine, rats were depleted of central norepinephrine stores with 6-OHDA and 4 days later MAC was determined before and after each dose of dexmedetomidine. Dexmedetomidine dose-dependently decreased MAC for halothane such that at the highest dose, halothane could be discontinued for up to 30 min without eliciting a response to tail-clamping. Idazoxan completely prevented the MAC-reducing action of dexmedetomidine, while naltrexone and 8-PT were without effect.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

α2 -肾上腺素能激动剂,如可乐定,可降低氟烷的剂量需求。美托咪定作为中枢α2 -肾上腺素能受体的完全激动剂,比可乐定更具选择性,它有活性(d)和无活性(l)两种异构体。我们使用d -异构体来探究这种α2 -激动剂在大鼠中产生最低肺泡有效浓度(MAC)降低效应的介导机制。在腹腔注射d -或l -美托咪定(10、30和100微克/千克)或生理盐水前后,测定大鼠(150 - 200克)对疼痛刺激无反应的氟烷剂量(氟烷MAC)。为了确定α2 -肾上腺素能受体是否介导右美托咪定(d -美托咪定)的MAC降低效应,给大鼠(每组剂量6只)腹腔注射10毫克/千克的高选择性α2 -拮抗剂咪唑克生进行预处理。为了确定右美托咪定降低MAC的作用是否部分通过阿片或腺苷受体介导,给大鼠组分别腹腔注射阿片拮抗剂纳曲酮(5毫克/千克)或A1腺苷拮抗剂8 -苯基茶碱(8 - PT,2.5毫克/千克)进行预处理。为了确定突触后机制是否介导右美托咪定的麻醉降低效应,用6 -羟基多巴胺耗尽大鼠中枢去甲肾上腺素储备,4天后在每次注射右美托咪定前后测定MAC。右美托咪定剂量依赖性地降低氟烷的MAC,以至于在最高剂量时,氟烷可停用长达30分钟而不引起夹尾反应。咪唑克生完全阻止了右美托咪定降低MAC的作用,而纳曲酮和8 - PT则无作用。(摘要截短至250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验